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Abstract: 
 
Verticillin A is a natural product isolated from fungal cultures and has displayed potent 
antibiotic, antiviral, nematocidal, and anticancer properties in vitro. While in vivo studies have 
been limited due to sparse supply, the in vivo efficacy data that does exist demonstrates potent 
anti-tumor activity in murine cancer models. The current study aims to investigate the 
pharmacokinetics and bioavailability of verticillin A in mice to provide guidance for further 
efficacy assessment in mouse models. A sensitive and specific liquid chromatography-tandem 
mass spectrometry method was developed and validated for the quantification of verticillin A in 
mouse plasma. Sample preparation was accomplished through protein precipitation, and 
chromatographic separation was achieved on an Agilent Zorbax Extend C18 column with a 
security guard cartridge C8 using a binary gradient with mobile phase A (water/0.1% formic 
acid) and B (ACN/0.1% formic acid) at a flow rate of 400 μl/min. Elution of verticillin A and 
internal standard, hesperetin, occurred at 4.87 and 2.06 min, respectively. The total 
chromatographic run time was 8 min, and the assay was linear in the concentration range of 1–
1000 nM. The within- and between day precisions and accuracy were in the range of 2.58–8.71 
and 90–105%, respectively. The assay was applied to determine plasma drug concentration in a 
mouse pharmacokinetic study. It was found that intraperitoneal dosing of 3 mg/kg resulted in 
high systemic exposure and achieved Cmax of 110 nM with plasma concentrations sustained 
above 10 nM for the 24-h duration of the study. Intravenous and oral dosing achieved 
observed Cmax of 73 nM and 9 nM, respectively. Oral dosing resulted in an approximate 9% 
bioavailability. Comparing with previously published in vitro studies that demonstrated 
verticillin A is active in the 20 nM to 130 nM range, the pharmacokinetic data demonstrate 
similar levels are achieved in mouse plasma via intravenous or intraperitoneal dosing routes. 
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Article: 
 
1. Introduction 
 
The epipolythiodioxopiperazine alkaloids are a class of fungal secondary metabolites that have 
drawn interest of scientists from a range of disciplines, including natural products 
chemists [1], [2], [3], synthetic organic chemists [4], [5], [6], mycologists [7], and 
pharmacologists [8], [9], [10], [11]. The first in this series, verticillin A, was isolated and 
characterized by Hitato and colleagues in the early 1970′s [12], [13]. The trivial name of this 
structural class was derived from the name of the fungus, Verticillium sp. [12]. In 2006, a 
research group crystalized verticillin A, thereby deriving its absolute configuration [14]. 
 
Verticillin A was found to be a potent antibiotic against Gram positive bacteria and 
mycobacteria [12]. Also, it has displayed antiviral [15] and nematocidal properties [16], with the 
latter being against Caenorhabditis elegans and Panagrellus redivivus. For most activities, the 
dimeric nature of the molecule, with a disulfide bridge in each monomer, is essential, as 
monomeric analogues of verticillin A are less potent [16]. 
 
The anticancer properties of verticillin A are the most investigated bioactivity. Even during its 
initial discovery, potent cytotoxicity against HeLa cells was noted, with an ED50 of 0.2 μg/ml (or 
0.29 μM) [12]. In the mid 1990s, Chu et al. studied verticillin A as an inhibitor of the c fos proto 
oncogene [17], where antitumor potential could be due to prevention of signal transduction, 
blocking some genes involved in cell proliferation. More recently, Liu and colleagues discovered 
the ability of verticillin A to induce cell cycle arrest in the G2 phase, noted in colon cancer cells 
both in vitro and in an in vivo xenograft model [18]. This same group found verticillin A to be a 
selective HMTase inhibitor, and in probing these effects in vivo, showed that verticillin A could 
be used to overcome 5-fluorouracil resistance in a murine colon cancer model [10]. In the last 
twelve months, since the time we initiated these studies, two more studies on the in vivo efficacy 
of verticillin A have been published [19], [20]. 
 
As a natural product that is biosynthesized in low yield within fungal cultures, in vivo data on 
verticillin A is quite limited despite its promising biological activities. Nonetheless, the two in 
vivo studies that have been conducted demonstrated anti-tumor activity in mouse models of 
colon cancer [18]. Given the challenges associated with limited supplies of verticillin A and the 
growing interest in its evaluation in mouse models, we conducted the studies described herein to 
gain understanding of the pharmacokinetic properties of this agent in mice. 
 
2. Materials and methods 
 
2.1. Chemicals and reagents 
 
Verticillin A was purified from culture MSX59553 from the Mycosynthetix fungal library, as 
detailed previously [2]. Hesperetin was used as internal standard (IS) and was purchased from 
Avanti Polar Lipids (Alabaster, AL). LC-grade acetonitrile (ACN), dimethyl sulfoxide (DMSO), 
water, methanol, cremophor EL, ethanol, and phosphate buffered saline (PBS, pH 7.4) were 
purchased from Fisher Scientific (Fair lawn, NJ). Formic acid was purchased from Sigma-
Aldrich (St. Louis, MO). Blank mouse plasma was purchased from Lampire Biological 
Laboratories, Inc (Pipersville, PA). 
 
2.2. Preparation of stock solutions and calibration standards 
 
A stock solution of verticillin A (0.72 mM, or 0.5 mg/ml) was prepared in a mixture of DMSO 
and ACN (1:1, v/v) and stored at −80 °C. A series of calibration standard solutions (10–10,000 
nM) were prepared freshly by diluting the stock solution stepwise using 50% ACN in H2O. A 
hesperetin stock solution (3.30 mM, or 1 mg/ml) was prepared in methanol and then diluted to 
make a working solution of 16.5 μM (or 5000 ng/ml). 
 
2.3. Sample preparation 
 
The standard and quality control (QC) samples were prepared by spiking 10 μl of serially diluted 
standard solutions of verticillin A and IS (5000 ng/ml) each into 100 μl blank mouse plasma to 
generate a calibration curve with final concentration of verticillin A ranging from 1 to1000 nM 
and QC samples with concentrations of 1, 3, 30, and 300 nM. The experimental samples of 
mouse plasma were prepared by spiking 10 μl of IS working solution to 100 μl plasma. All the 
standards, QC, and the experimental samples were extracted with 1 ml of ACN by vortex mixing 
for 1 min, and then were centrifuged for 10 min at 13,500 rpm. The supernatant was transferred 
into a glass tube and evaporated under a gentle stream of Nitrogen. The residue was then 
reconstituted with 200 μl of 50% ACN, followed by vortex mixing for 1 min. These solutions 
were transferred into microcentrifuge tubes and centrifuged at 13,500 rpm for 10 min at 4 °C. 
The supernatant was transferred into Thermo PAL autosampler vials and 20 μl was injected for 
LC–MS/MS analysis. 
 
2.4. LC–MS/MS analysis 
 
The assay was developed on a LC–MS system consisting of a Thermo Accela UHPLC pump, 
Thermo PAL autosampler and Thermo TSQ Discovery triple quadrupole mass spectrometer with 
XCalibur and LCquan software. The chromatographic separation of the analytes was achieved on 
an Agilent Zorbax Extend C18 analytical column (3.5 μm x 2.1 mm I.D. x 50 mm) with a 
security guard cartridge C8, and the column temperature was maintained at 40 °C. Linear 
gradient elution was performed at a flow rate of 400 μl/min with water/0.1% formic acid as 
mobile phase A, and ACN/0.1% formic acid as mobile phase B: 0.0 min (70% A and 30% B), 
5.0 min (35% A and 65% B), 5.10 min (5% A and 95% B), 6.50 min (5% A and 95% B), 6.6 min 
(70%A and 30%B) and 8.0 min (70% A and 30%B) for 8 min. The autosampler temperature was 
set at 4 °C. 
 
2.5. Method validation 
 
The validation experiments were performed in accordance with the FDA guidance for 
bioanalytical methods. The experiments included selectivity, linearity, precision and accuracy, 
matrix effects, carryover, and stability tests. Standards and QC sample solutions were prepared 
as described in the sample preparation section to generate calibration curves with plasma 
concentrations of 1–1000 nM and QC samples at a concentration of 1, 3, 30, and 300 nM in 
mouse plasma. Within-day and between-day precision and accuracy were evaluated using 
replicate samples of 6 (n = 6) at four QC concentration levels. 
 
Carryover effect was evaluated by injecting a blank sample following the injection of the highest 
concentration standard sample (1000 nM). The recovery was calculated by comparing the peak 
areas of verticillin A in QC samples with those of corresponding neat solution added in the 
supernatant of the processed blank plasma samples. The matrix effect was assessed by 
comparing the peak areas of the spiked samples after extraction of blank plasma with those of 
neat solutions. The stability of verticillin A was performed at four concentrations indicated above 
in triplicates under all experimental conditions, including auto sampler at 4 °C for 12 h after 
extraction, and bench-top for 4 h, three cycles of freeze-thaw, and one month storage at −80 °C 
before extraction. 
 
2.6. Animal study 
 
Single-dose pharmacokinetics of verticillin A was evaluated in mice. All animal experiments 
were performed following the protocols approved by the Institutional Animal Care and Use 
Committees (IACUCs) of the Ohio State University. 5–6 week-old female ICR mice (22–28 g) 
were purchased from Harlan Laboratories, Inc. (Indianapolis, IN, USA) and housed in barrier 
rodent facility with free access to standard chow diet and water for one week prior to the 
experiment. Verticillin A was initially dissolved in DMSO to make 6 mg/ml stock solution and 
then diluted with a mixture of Cremophor EL-ethanol-PBS (10:5:85, v/v/v) by 20 fold according 
to the previously published animal study [10] and personal communication with the 
corresponding author. Prior to the start of the experiment, animals were randomly divided into 
three groups (n = 10/group). One animal per time point was included in this study due to the 
limited supply of verticillin A. The first group received verticillin A intravenously at 1 mg/kg 
(1.43 μmol/kg) by tail vein bolus injection (IV, dose volume = 3.3 ml/kg). The second and third 
groups were given verticillin A at a dose of 3 mg/kg (4.30 μmol/kg) by oral gavage (PO) and 
intraperitoneal (IP) administration, respectively (dose volume = 10 ml/kg). These doses were 
chosen due to the limited solubility of verticillin A and the maximum dosing volumes allowed. 
Blood samples were collected via cardiac puncture into the heparinized polypropylene tubes at 
0.083, 0.17, 0.33, 0.5, 1, 2, 4, 6, 8, and 24 h after dosing. Plasma samples were harvested by 
centrifugation at 1000g for 5 min and then processed for quantification of verticillin A by LC–
MS/MS (described in Sections 2.3. and 2.4.). Pharmacokinetic analyses were performed by non-
compartmental methods using Phoenix WinNonlin version 6.3 (Pharsight Corporation, Mountain 
view, CA). 
 
3. Results and discussion 
 
3.1. Method development 
 
Chromatographic and mass spectrometric conditions were optimized to increase signal response 
of analytes and improve peak shape. Positive electrospray ionization was selected due to the 
superior signal intensity for both verticillin A and hesperetin. Transitions with maximum signal 
to noise ratios were chosen for the quantification of verticillin A and hesperetin; these were 
m/z 697.18 → (383.29 + 615.35) and 303.06 → 153.01, respectively (Fig. 1), and a detailed 
analysis of the fragmentation pattern for verticillin A and related analogues was recently 
published [21]. The C18 column with a security guard cartridge C8, in combination with a 
gradient elution, resulted in the efficient separation and elution of verticillin A. Formic acid was 
added to the mobile phases to improve peak shape. Protein precipitation using acetonitrile was 
found to be appropriate with minimal matrix effects and high recoveries. 
 
 
Fig. 1. Chemical structures and mass fragmentation spectra of (A) verticillin A and (B) 
hesperetin (IS) along with their proposed product ion structures. 
 
3.2. Assay validation 
 
3.2.1. Selectivity, linearity, accuracy and precision 
 
The chromatograms of blank mouse plasma spiked with LLOQ of verticillin A (1 nM) and IS are 
shown in Fig. 2 with retention times of 4.87 min for verticillin A and 2.06 min for IS. No 
interference peaks were observed in the mouse plasma matrix at the retention time of verticillin 
A and IS, indicating good selectivity of the method (Fig. 2). The linearity was calculated using 
1/X2 weighting and a linear curve was obtained in the range of 1–1000 nM with correlation 
coefficient (r2) of 0.9926. The precision and accuracy for verticillin A were 2.58-8.71% and 90–
105%, respectively, which are well within the acceptable limits (Table 1), suggesting that the 
developed method was precise and accurate for the quantification of verticillin A over the tested 
concentration range. 
 
3.2.2. Carry over, matrix effect and recovery 
 
No carryover effects were observed as indicated by lack of signal response in the blank plasma 
sample injected following the injection of the highest standard sample (data not shown). Matrix 
effects evaluated at four QC levels ranged from 92 to 99%, suggesting that matrix components 
have little effects on verticillin A signal. The recovery ranged from 90 to 101% (Table 2) for four 
tested levels, indicating efficient and high recovery of the method. 
 
3.2.3. Stability 
 
Verticllin A was found to be stable in mouse plasma under different tested conditions with the 
deviations of the measured concentration <10% from the nominal concentration (Table 3), 
indicating no significant loss of verticillin A and IS under experimental conditions. 
 
 
Fig. 2. Representative SRM chromatograms of verticillin A (left) and hesperetin (right) in: A. 
blank (analyte and IS free) sample, B. zero sample (analyte-free plasma spiked with IS), C. 
plasma spiked with analytes (1 nM, LLOQ) and IS and D. plasma sample at 24 h after 
intraperitoneal administration of verticillin A (3 mg/kg). NL: Normalized intensity level. 
 
Table 1. Within and between-day accuracy and precision for verticillin A in 
mouse plasma (n = 6). 
Nominal conc. 
(nM) 
Within-day Between-day 
Mean measured conc. 
(nM) 
Accuracy 
(%) 
Precision 
(%CV) 
Mean measured conc. 
(nM) 
Accuracy 
(%) 
Precision 
(%CV) 
1 0.99 98.6 6.61 1.01 101 6.94 
3 2.72 90.7 3.67 2.99 99.6 8.15 
30 27.7 92.3 2.59 31.6 105 8.71 
300 270 90.0 3.27 309 103 8.15 
Accuracy (%) was determined as mean measured concentration/nominal concentration × 100%. 
Precision (%CV) was determined as standard deviation/mean × 100%. 
 
Table 2. Recovery & matrix effects for verticillin A in mouse plasma (n = 3). 
Nominal conc. (nM) Recovery Matrix effect % nominal conc. %CV % nominal conc. %CV 
1 101 4.31 92 8.88 
3 95 12.8 97 10.4 
30 95 5.82 94 6.97 
300 90 5.15 99 4.99 
%CV was determined as standard deviation/mean × 100%. 
 
Table 3. Stability of verticillin A in mouse plasma under different storage conditions (n = 3). 
Nominal conc. (nM) Measured concentration (nM)
a 
Freeze-thaw Benchtop on ice 4 h Autosampler 12 h (4 °C) One month storage (−80 °C) 
1 0.93 ± 0.04 0.91 ± 0.02 0.95 ± 0.03 1.05 ± 0.06 
3 3.17 ± 0.06 2.87 ± 0.29 2.77 ± 0.19 3.32 ± 0.09 
30 32.4 ± 0.88 28.4 ± 1.37 29.3 ± 1.42 32.2 ± 0.39 
300 310 ± 6.8 280 ± 16 268 ± 19 324 ± 2.0 
a Mean ± standard deviation of three measurements. 
 
3.3. Pharmacokinetic analysis and bioavailability 
 
The plasma concentration-time profiles of verticillin A were determined after a single IV dose of 
1 mg/kg or a single IP or PO dose of 3 mg/kg (Fig. 3), and the pharmacokinetic parameters were 
estimated by noncompartmental analysis (Table 4). Following IV administration, the maximum 
observed plasma concentration (Cmax) was 72.9 nM and occurred at our first sample time of 
5 min. The IV data demonstrated a rapid distribution phase where plasma concentrations 
declined below 10 nM within 1 h followed by a terminal phase with a long half-life of 
approximately 20 h suggesting a slow elimination rate. IP dosing showed similar kinetics with a 
110 nM Cmax and a terminal phase half-life of approximately 11 h. Plasma levels were sustained 
above 10 nM throughout the 24 h period after IP dosing. The observed Cmax levels with both IV 
and IP dosing, and the higher sustained plasma concentrations after IP dosing indicate active 
concentrations are at least achieved in plasma in vivo. This is based on prior in vitro studies 
demonstrating activity in the 20–50 nM range [10], [22] and 24-h IC50 values of 30–122 nM in 
an array of cancer cell types [2], [18]. Oral administration of verticillin A at 3 mg/kg resulted 
in Cmax of 9.13 nM at 0.5 h. The absolute oral bioavailability (F%) was determined to be 
approximately 9%, based on the areas under the concentration vs. time curves from time zero to 
last measurable time point (AUClast) values estimated from IV and PO administration. Following 
IP administration, the systemic availability was approximately 170%. The calculated 
bioavailability above 100% is likely a result of the limited data from single mice per time point 
and the fact that the earliest sample collected was at 5 min when plasma concentrations are 
rapidly declining after IV administration (i.e. a significant portion of the IV AUC likely occurs 
prior to the 5 min time point). Despite the challenges of this study due to limited supply of 
this natural product, this study reports the first in vivo pharmacokinetic data for verticillin A. 
 
 
Fig. 3. Plasma concentration-time profiles of verticillin A in mice following IP, IV, and PO 
administration. 
 
Table 4. Pharmacokinetic parameters of verticillin A following IP, IV, and PO administration to 
mice. 
Parameter IV, 1 mg/kg (1.43 μmol/kg) IP, 3 mg/kg (4.30 μmol/kg) PO, 3 mg/kg (4.30 μmol/kg) 
Cmax (nM) 72.9 110 9.13 
AUClast (nM h) 152 775 39.9 
AUC0-∞_obs 290 970 43.7 
T1/2 (h) 19.91 10.92 1.75 
Tmax (h) 0.08 0.5 0.5 
CL (L/h/kg)a 4.94 2.61 98.45 
Vd (L/kg)b 142 70 249 
F (%) 100 170 8.76 
AUC0-∞_obs, area under the observed concentration-time curve extrapolated to infinity. 
a Clearance; CL/F for IP and PO administration. 
b Volume of distribution; CL/F for IP and PO administration. 
 
4. Conclusions 
 
Verticillin A is a natural product isolated from fungal cultures. Despite the challenges in 
harvesting ample quantities of this agent, it has gained a great deal of interest from cancer 
researchers due to its potent anticancer activity in vitro [2] and in vivo [18], [19], [20] as well as 
its selectivity as an HMTase inhibitor to suppress colon cancer cell immune escape and 
chemoresistance [10]. Herein we present the development and validation of a sensitive LC–
MS/MS assay for quantification of verticillin A in mouse plasma with linearity from 1 to 
1000 nM. The assay demonstrates within- and between-day precision <9% and accuracy ranging 
from 90% to 105%. Despite limited supplies of this agent, we harvested enough compound to 
administer 1 mg/kg (intravenous) or 3 mg/kg (oral and intraperitoneal) doses of verticillin A to 
30 ICR mice and applied the LC–MS/MS assay to measure plasma concentrations after the mice 
were euthanized at 10 time points in each dosing group. While these data are limited, this study 
provides the first glimpse of the pharmacokinetic behavior of verticillin A after PO, IP and IV 
administration in mice. The relatively high exposures after IP and IV dosing suggest these are 
suitable routes of administration for further in vivo efficacy studies of verticillin A. 
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